LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between ALLOS THERAPEUTICS, INC., a Delaware corporation and MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED a Bermuda corporationLicense, Development and Commercialization Agreement • August 4th, 2011 • Allos Therapeutics Inc • Pharmaceutical preparations • New York
[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
THIRD AMENDMENT TO LICENSE AGREEMENTLicense Agreement • August 4th, 2011 • Allos Therapeutics Inc • Pharmaceutical preparations
This THIRD AMENDMENT TO LICENSE AGREEMENT (this “Third Amendment”), dated as of May 10, 2011 is entered into between SRI INTERNATIONAL, a California not-for-profit corporation (“SRI”), SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, a New York not-for-profit corporation (“SKI”), SOUTHERN RESEARCH INSTITUTE, an Alabama not-for-profit corporation (“SoRI” and, together with SRI and SKI, the “Licensor”), and ALLOS THERAPEUTICS, INC., a Delaware corporation (“Allos”). Allos and Licensor are each sometimes individually referred to herein as a “Party” and collectively as the “Parties”.
ContractSupply Agreement • August 4th, 2011 • Allos Therapeutics Inc • Pharmaceutical preparations • New York
[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
